NASDAQ:CERE Cerevel Therapeutics (CERE) Stock Price, News & Analysis → Protect Your Bank Account from China (From Behind the Markets) (Ad) Free CERE Stock Alerts $41.62 +0.15 (+0.36%) (As of 11:55 AM ET) Add Compare Share Share Today's Range$41.48▼$41.6850-Day Range$40.02▼$42.7552-Week Range$19.59▼$43.59Volume162,171 shsAverage Volume1.37 million shsMarket Capitalization$7.58 billionP/E RatioN/ADividend YieldN/APrice Target$42.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Cerevel Therapeutics alerts: Email Address Cerevel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.11 Rating ScoreUpside/Downside2.5% Upside$42.67 Price TargetShort InterestBearish8.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 7 Articles This WeekInsider TradingSelling Shares$2.11 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.63) to ($2.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.14 out of 5 starsMedical Sector903rd out of 913 stocksPharmaceutical Preparations Industry426th out of 430 stocks 1.1 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 1 buy rating, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageCerevel Therapeutics has received no research coverage in the past 90 days.Read more about Cerevel Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.34% of the float of Cerevel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCerevel Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Cerevel Therapeutics has recently increased by 2.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERE. Previous Next 2.5 News and Social Media Coverage News SentimentCerevel Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Cerevel Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows1 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,105,000.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Cerevel Therapeutics is held by insiders.Percentage Held by Institutions87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cerevel Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.63) to ($2.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -15.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -15.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 11.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cerevel Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.Get the full story here >>> About Cerevel Therapeutics Stock (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More CERE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERE Stock News HeadlinesJune 18 at 6:13 AM | globenewswire.comCEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoing Investigation into the Deal PriceJune 13, 2024 | globenewswire.comCEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Encourages Investors to Contact the FirmJune 18, 2024 | Behind the Markets (Ad)The Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.June 11, 2024 | globenewswire.comCEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urges Shareholders to Contact the Firm About Your RightsJune 11, 2024 | globenewswire.comCEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urges Shareholders to Contact the Firm About Your RightsJune 8, 2024 | globenewswire.comCEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into the $45 Merger Offer, Contact the Firm About Your RightsJune 5, 2024 | globenewswire.comCEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law about the $45 Merger Offer from AbbVieJune 4, 2024 | seekingalpha.comCerevel Therapeutics: Time For A Risk Arbitrage Play?June 18, 2024 | Behind the Markets (Ad)The Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.June 3, 2024 | globenewswire.comACQUISITION NEWS: Cerevel's (Nasdaq: CERE) $45 Merger Offer is Being Investigated for Being Too Low, Shareholders are Encouraged Contact BFA LawMay 30, 2024 | prnewswire.comCEREVEL INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and Encourages Investors to Contact the FirmMay 29, 2024 | finance.yahoo.comPipeline for Acquisition Financing Shrinks, in Boon for CreditMay 29, 2024 | businesswire.comCalling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesMay 20, 2024 | prnewswire.comNOTICE OF INVESTIGATION: Kaskela Law LLC Announces Shareholder Investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and Encourages Investors to Contact the FirmMay 20, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cerevel Therapeutics Holdings (CERE), Cullinan Management (CGEM) and Vincerx Pharma Inc (VINC)May 19, 2024 | morningstar.comCerevel Therapeutics Holdings Inc Ordinary Shares CEREMay 18, 2024 | stockhouse.comBFA LLP Reminds Cerevel Therapeutics Shareholders of the Investigation into Merger with AbbVie and Encourages Investors to Contact the FirmMay 15, 2024 | stockhouse.comMERGER ALERT CERE Is $45 per CERE Share Fair? Top Law Firm BFA LLP Investigating Cerevel Therapeutics Merger with AbbVieApril 30, 2024 | finance.yahoo.comAddex stock tanks after lead drug flops in Phase II epilepsy trialApril 26, 2024 | finance.yahoo.comTop 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talksApril 22, 2024 | markets.businessinsider.comHold Rating Maintained for Cerevel Post-Positive Phase 3 Data Amid Pending AbbVie AcquisitionApril 18, 2024 | benzinga.comSoon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease StudyApril 18, 2024 | msn.comAbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drugApril 18, 2024 | reuters.comCerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage studyApril 18, 2024 | finance.yahoo.comCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseApril 18, 2024 | globenewswire.comCerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's DiseaseApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)See More Headlines Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/18/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees334Year FoundedN/APrice Target and Rating Average Stock Price Target$42.67 High Stock Price Target$45.00 Low Stock Price Target$31.00 Potential Upside/Downside+2.5%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-432,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-98.94% Return on Assets-45.07% Debt Debt-to-Equity Ratio0.60 Current Ratio10.22 Quick Ratio10.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.71 per share Price / Book11.22Miscellaneous Outstanding Shares182,200,000Free Float172,903,000Market Cap$7.58 billion OptionableOptionable Beta1.42 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. N. Anthony Coles Jr. (Age 64)M.P.H., Executive Chairman Comp: $1.14MMr. Mark Bodenrader (Age 51)VP of Finance & Chief Accounting Officer Comp: $496.17kDr. John J. Renger Ph.D. (Age 55)Chief Scientific Officer Comp: $779.75kDr. Ramiro Sanchez M.D. (Age 63)Chief Medical Officer Comp: $805.13kMr. Ronald C. Renaud Jr. (Age 55)M.B.A., President, CEO & Director Dr. Susan Altschuller M.B.A. (Age 42)Ph.D., Chief Financial Officer Mr. Matthew CalistriVice President of Investor RelationsMr. Scott M. Akamine J.D. (Age 39)Chief Legal Officer & Corporate Secretary Comp: $444.74kMr. Kenneth A. DiPietro (Age 65)Chief Human Resources Officer Ms. Kathleen Tregoning M.A. (Age 53)Chief Corporate Affairs Officer Comp: $600.79kMore ExecutivesKey CompetitorsCNX ResourcesNYSE:CNXWarrior Met CoalNYSE:HCCArch ResourcesNYSE:ARCHHallador EnergyNASDAQ:HNRGAlnylam PharmaceuticalsNASDAQ:ALNYView All CompetitorsInsiders & InstitutionsWalleye Trading LLCBought 500 shares on 5/17/2024Ownership: 0.000%Comerica BankSold 69,207 shares on 5/17/2024Ownership: 0.000%Blackstone Inc.Bought 20,651 shares on 5/16/2024Ownership: 0.019%Black Maple Capital Management LPBought 15,702 shares on 5/16/2024Ownership: 0.009%Jane Street Group LLCSold 27,500 shares on 5/16/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CERE Stock Analysis - Frequently Asked Questions Should I buy or sell Cerevel Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares. View CERE analyst ratings or view top-rated stocks. What is Cerevel Therapeutics' stock price target for 2024? 9 equities research analysts have issued 12 month price objectives for Cerevel Therapeutics' shares. Their CERE share price targets range from $31.00 to $45.00. On average, they anticipate the company's stock price to reach $42.67 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price. View analysts price targets for CERE or view top-rated stocks among Wall Street analysts. How have CERE shares performed in 2024? Cerevel Therapeutics' stock was trading at $42.40 at the beginning of the year. Since then, CERE shares have decreased by 1.8% and is now trading at $41.62. View the best growth stocks for 2024 here. When is Cerevel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our CERE earnings forecast. How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) released its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by $0.12. What ETFs hold Cerevel Therapeutics' stock? ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), iShares Neuroscience and Healthcare ETF (IBRN), First Trust Merger Arbitrage ETF (MARB), IQ Merger Arbitrage ETF (MNA), AltShares Event-Driven ET (EVNT), AltShares Merger Arbitrage ETF (ARB), ProShares Merger ETF (MRGR) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO). Who are Cerevel Therapeutics' major shareholders? Cerevel Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.11%), Healthcare of Ontario Pension Plan Trust Fund (0.46%), Gabelli Funds LLC (0.35%), GABELLI & Co INVESTMENT ADVISERS INC. (0.25%), Tokio Marine Asset Management Co. Ltd. (0.21%) and Price T Rowe Associates Inc. MD (0.18%). Insiders that own company stock include Abraham Ceesay, Bain Capital Investors Llc, Deval L Patrick, John Renger, Kenneth Dipietro, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc, Ramiro Sanchez, Ronald C Renaud Jr, Scott Akamine and Susan Altschuller. View institutional ownership trends. How do I buy shares of Cerevel Therapeutics? Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CERE) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerevel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.